11,515 Shares of Merck & Co., Inc. $MRK Acquired by Canandaigua National Trust Co of Florida

Key Points

• Canandaigua National Trust Co. of Florida initiated a position of 11,515 Merck shares worth approximately $1.67 million, making Merck its 24th-largest holding. Institutional investors and hedge funds collectively own 76.07% of MRK.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $148.80; Morgan Stanley also reiterated its “Overweight” rating despite trimming its target to $177.
• Merck’s outlook remains supported by Keytruda and its broader pipeline, but a Dutch court ruling blocking subcutaneous Keytruda sales in eight European markets presents a potential growth and revenue risk.

Canandaigua National Trust Co of Florida purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 11,515 shares of the company's stock, valued at approximately $1,673,000. Merck & Co., Inc. makes up about 0.9% of Canandaigua National Trust Co of Florida's holdings, making the stock its 24th biggest position.

Other institutional investors also recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock valued at $29,169,479,000 after acquiring an additional 1,073,507 shares during the period. State Street Corp lifted its position in Merck & Co., Inc. by 0.9% in the second quarter. State Street Corp now owns 120,413,256 shares of the company's stock worth $15,573,754,000 after purchasing an additional 1,087,583 shares during the period. Wellington Management Group LLP boosted its stake in Merck & Co., Inc. by 2.3% during the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock valued at $11,083,033,000 after purchasing an additional 1,934,312 shares in the last quarter. Bank of America Corp DE boosted its stake in Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Merck & Co., Inc. by 3.5% during the 4th quarter. Invesco Ltd. now owns 20,546,185 shares of the company's stock valued at $2,162,691,000 after purchasing an additional 701,249 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Morgan Stanley maintained an “overweight” rating on Merck while trimming its price target from $179 to $177, still implying substantial upside. The rating reflects confidence in Keytruda, Merck’s broader product portfolio and its longer-term outlook. Morgan Stanley price target update
• Positive Sentiment: Recent commentary argues that Merck’s pullback over the past month may represent a buying opportunity. Keytruda remains the primary growth driver, while newer products and pipeline assets could help support growth after 2028. Merck stock valuation and outlook
• Neutral Sentiment: Sell-side analysts collectively rate Merck & Co. (MRK) a “moderate buy,” indicating generally favorable sentiment but not unanimous conviction. Merck analyst rating
• Negative Sentiment: A Dutch court ruled for Halozyme Therapeutics in a patent dispute, barring Merck from selling subcutaneous Keytruda in eight European markets. The injunction threatens the rollout of a potentially more convenient version of Merck’s largest drug and could delay related revenue opportunities in Europe. Merck injectable Keytruda European injunction

Analysts Set New Price Targets

MRK has been the topic of a number of research reports. The Goldman Sachs Group boosted their price objective on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a "buy" rating in a research note on Friday, August 21st. Argus lifted their target price on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a "buy" rating in a report on Tuesday, August 25th. Sanford C. Bernstein boosted their price target on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a "market perform" rating in a research report on Tuesday, August 4th. Weiss Ratings upgraded shares of Merck & Co., Inc. from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, August 25th. Finally, Leerink Partners upped their price target on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the company an "outperform" rating in a report on Wednesday, September 9th. Seventeen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of "Moderate Buy" and an average price target of $148.80.

Merck & Co., Inc. Price Performance

Shares of MRK traded up $0.72 during trading hours on Wednesday, hitting $142.66. 6,349,422 shares of the company were exchanged, compared to its average volume of 10,674,509. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The company has a market capitalization of $351.96 billion, a PE ratio of 114.12, a PEG ratio of 6.08 and a beta of 0.21. The firm has a fifty day simple moving average of $143.10 and a 200-day simple moving average of $127.76. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the previous year, the firm earned $2.13 earnings per share. Merck & Co., Inc.'s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 272.00%.

Insider Buying and Selling

In other news, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares of the company's stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Chirfi Guindo sold 15,000 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. This represents a 24.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 228,238 shares of company stock valued at $29,977,783. Company insiders own 0.17% of the company's stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.